The estimated Net Worth of Robert S Attiyeh is at least $1.35 Million dollars as of 23 August 2014. Robert Attiyeh owns over 4,856 units of Myriad Genetics stock worth over $1,320,544 and over the last 21 years Robert sold MYGN stock worth over $33,990.
Robert has made over 4 trades of the Myriad Genetics stock since 2004, according to the Form 4 filled with the SEC. Most recently Robert exercised 4,856 units of MYGN stock worth $127,616 on 23 August 2014.
The largest trade Robert's ever made was exercising 12,000 units of Myriad Genetics stock on 8 July 2014 worth over $223,440. On average, Robert trades about 1,986 units every 385 days since 2003. As of 23 August 2014 Robert still owns at least 50,249 units of Myriad Genetics stock.
You can see the complete history of Robert Attiyeh stock trades at the bottom of the page.
Robert's mailing address filed with the SEC is 210 SOUTH CANYON VIEW DRIVE, , LOS ANGELES, CA, 90049.
Over the last 22 years, insiders at Myriad Genetics have traded over $51,783,466 worth of Myriad Genetics stock and bought 61,160 units worth $1,252,955 . The most active insiders traders include Jerry S Lanchbury, Peter D Meldrum, and Arthur H Jr Hayes. On average, Myriad Genetics executives and independent directors trade stock every 18 days with the average trade being worth of $563,312. The most recent stock trade was executed by Heinrich Dreismann on 9 September 2024, trading 10,000 units of MYGN stock currently worth $270,500.
myriad genetics inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. myriad is focused on three strategic imperatives: maintaining leadership in an expanding hereditary cancer market, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets. for more information on how myriad is making a difference, please visit the company's website: www.myriad.com.
Myriad Genetics executives and other stock owners filed with the SEC include: